NEW BRUNSWICK, N.J. (PRWEB)
April 09, 2020

Natreon announces publication of a randomized, double-blind clinical study on the effect of trivalent chromium, amla and shialjit when combined with fish oil. The study shows evidence that the trivalent chromium, amla and shilajit complex significantly improves the efficacy of fish oil in addressing cardiovascular risk factors.

In this randomized, double-blind, parallel group study, 59 type 2 diabetic subjects, who have already been on a stable dose of metformin, in three groups, completed the study: Group A, fish oil 2000 mg; Group B, fish oil 2000 mg + trivalent chromium, amla, shilajit complex 10 mg (200 μg of Cr3+); and Group C, fish oil 2000 mg + chromium, amla, shilajit combination 20 mg (400 μg of Cr3+) daily for 12 weeks (2000 mg of fish oil contained 600 mg of EPA and 400 mg of DHA). Endothelial function, as reflection index (RI), biomarkers of oxidative stress – malondialdehyde (MDA), nitric oxide (NO), glutathione (GSH), and inflammatory biomarkers high sensitivity C-reactive protein (hsCRP), inter-cellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), Endothelin-1 (ET-1) were evaluated at baseline, and 4 and 12 weeks. Lipid profile, platelet aggregation and glycosylated hemoglobin were evaluated at baseline and at 12 weeks.

Twelve week results show that fish oil by itself, at a dose of 2000 mg (600 mg of EPA + 400 mg of DHA) per day, led to significant (p≤0.05 to 0.0001) but modest improvement in cardiovascular parameters – endothelial function as RI from −2.38±0.75 to −3.92±0.60, MDA -0.88%, NO 4.94%, GSH 2.64%, hsCRP -2.09%, ICAM-1 -6.9%, VCAM-1 -5.85%, ET-1 -9.43%, TC -7.53%, HDL-C 4.74%, LDL-C -11.06%, VLDL-C -10.23%, triglycerides -10.1% . However, when the chromium, amla, shilajit complex was added to fish oil, especially at the 20 mg/day (400 mcg of Cr3+) dose, there were highly significant (p≤0.0001) improvements in all the parameters tested (RI from −2.04±0.79 to −8.73±1.36), MDA -21.29%, NO 38.79%, GSH 22.44%, hsCRP -63.4%, ICAM-1 -29.2%, VCAM-1 -38.64%, ET-1 -24.19%, TC -23.68%, HDL-C 25.11%, LDL-C -37.02%, VLDL-C -28.06%, triglycerides -28.11%.

Dr. Sanni Raju, CEO of Natreon states, “it is noteworthy that the triglycerides decreased significantly in the chromium, amla, shilajit complex groups although the dose of fish oil was only 2 g/day and the baseline triglyceride levels were only about 200 mg/dL, because fish oil is known to work better at 4g/day dose, and in hypertriglyceridemia state (triglyceride levels ≥500 mg/dL). In addition to this study, a second clinical study will soon be published evaluating the effect of trivalent chromium, amla, and shilajit in combination with fish oil in a population with health parameters associated with metabolic syndrome.”

About Natreon

Natreon is a leader in nutritional ingredient innovation, quality and research. Trusted by manufacturers for over 20 years, Natreon’s patented ingredients are derived from nature and founded on evidence-based Ayurveda. Committed to quality, its extracts are purified and standardized using proprietary process technology and controls that result in optimal levels of bioactive constituents. Natreon’s ingredients have been used in over 50 clinical trials that have supported 40 publications and 24 active patents. Natreon brings storied knowledge and expertise in botanical cultivation and extraction, and its ingredients are sustainably sourced through an integrated supply chain to ensure quality and potency. Natreon has its global headquarters in New Jersey and a state-of-the-art R&D facility in Kolkata, India. Natreon’s products include: Sensoril® ashwagandha, PrimaVie® shilajit, Capros® amla, Crominex®, AyuFlex®, Ayuric®, and introducing PhytoBGS®. For more information, visit: https://natreoninc.com/.

Contact:

Ally Coda – Marketing & Public Relations

Natreon, Inc.

2-D Janine Place

New Brunswick, NJ 08901

Tel: 732-296-1080

E-mail: ally@natreoninc.com

Share article on social media or email: